Clinical Trials Sponsored by Merck Inc., Philippines

Total 491 results

Merck KGaA, Darmstadt, Germany
Merck Inc., Philippines

Completed

A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes

Hypertension

Philippines
Asian Foundation for Tropical Medicine Inc.
Pfizer; Southern Philippines Medical Center; Philippine Children's Medical Center...

Active, not recruiting

PCV13 Impact on Pneumococcal Nasopharyngeal Carriage Study (IMPACT)

Community-acquired Pneumonia

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Recruiting

"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program" (RAISE)

Schizophrenia | Major Depressive Disorder

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy

NSAID Induced Gastropathy

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance

Hyperlipidemia
Otsuka Pharmaceutical, Inc., Philippines

Completed

Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines (ASCEND)

Polyneuropathy

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room

Asthma

Philippines
University of the Philippines
Calmoseptine, Inc.

Completed

Treatment of Incontinence Associated Dermatitis in Older Children and Adults

Incontinence Associated Dermatitis

Philippines
Corbridge Group Philippines, Inc.
Alfasigma S.p.A.

Unknown

The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease (DEFINE)

Chronic Kidney Disease

Philippines
University of the Philippines
Calmoseptine, Inc.

Completed

Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants

Diaper Dermatitis

Philippines
Makati Medical Center
A. Menarini Philippines, Inc.

Completed

Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging

Cutaneous Photoaging

Philippines
Otsuka Pharmaceutical, Inc., Philippines
Otsuka Pharmaceutical Co., Ltd.

Terminated

Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Pulmonary Disease, Chronic Obstructive

Philippines
University of the Philippines
St. Luke's Medical Center, Philippines; De La Salle University Medical Center; University of Santo Tomas Hospital, Philippines and other collaborators

Unknown

Neurologic Manifestations of COVID-19 (CORONA)

Coronavirus Disease 2019

Philippines
PATH
Quintiles, Inc.; Mahidol University; Research Institute for Tropical Medicine...

Completed

Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Encephalitis, Japanese B

Philippines
United Nations Office on Drugs and Crime (UNODC)
Polytechnique University of the Philippines; Anti-Drug Abuse Councils, LGUs...

Enrolling by invitation

Assessing the Feasibility of Providing a Family Skills Intervention "Strong Families" for Families in the Philippines. (SF_RCT_POPHL)

Family Relationship | Parenting Skills

Philippines
McMaster University
Merck Canada Inc.

Recruiting

Assessing Knowledge, Beliefs and Attitudes Toward HPV Vaccination Among Parents in North West, Cameroon

Vaccine Refusal

Cameroon
Queen's University
Merck Canada Inc.

Not yet recruiting

Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living With HIV

Cervical Cancer
Kineta Inc.
Merck Sharp & Dohme LLC

Recruiting

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Melanoma | Sarcoma | Kidney Cancer | Carcinoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Solid Tumor | Prostate Cancer | Colo-rectal Cancer | Thyroid Cancer | Uterine Cancer

United States
NextCure, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer | Advanced or Metastatic Solid Tumors | Microsatellite Instability Low | Microsatellite Instability High | Microsatellite Stable | Head Neck Cancer

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Melanoma | Carcinoma, Hepatocellular | Colorectal Neoplasms

Spain, United States, United Kingdom, Japan, France
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma

United States, Canada, United Kingdom, Japan, Australia, Argentina, Chile, Israel
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Melanoma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer

United States, Canada
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil, Norway
Inhibrx, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Gastric Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Urothelial Carcinoma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Carcinoma, Renal Cell

United States, Colombia, Canada, Australia, Finland, Japan, United Kingdom, Brazil, Chile, China, Croatia, Czechia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Norway, Philippines, Polan... and more
Genexine, Inc.
Merck Sharp & Dohme LLC

Completed

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Triple Negative Breast Cancer

Korea, Republic of
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Seagen Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Neoplasms

United States, Spain, Korea, Republic of, Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10)

Head and Neck Squamous Cell Carcinoma

United States, Australia, Brazil, Canada, China, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Endometrial Neoplasms

France, Canada, United States, Spain, United Kingdom, Italy, Taiwan, Korea, Republic of, Colombia, Australia, New Zealand, Brazil, Turkey, Poland, Israel, Argentina, Germany, Ireland, Japan, Mexico, Russian Federation
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Osteosarcoma

Korea, Republic of, New Zealand, Spain, United States, Sweden, Taiwan, Singapore, Hong Kong, United Kingdom, France, Belgium, Switzerland, Australia, Ireland, Canada, Israel, Italy, Austria, Czechia, Finland, Netherlands
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Malignant Melanoma

China
DNAtrix, Inc.
Merck Sharp & Dohme LLC

Completed

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

Nervous System Diseases | Glioma | Glioblastoma | Neuroectodermal Tumors | Brain Cancer | Gliosarcoma | Brain Neoplasm | Malignant Brain Tumor | Neoplasm, Neuroepithelial | Neoplasm by Histologic Type | Neoplasm, Nerve Tissue

United States, Canada
Merck Sharp & Dohme LLC
Quintiles, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

Melanoma | Carcinoma, Non-Small-Cell Lung | Breast Neoplasm | Metastases of Central Nervous System
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612) (ESAQUALITY)

Psoriasis
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED) (TIPS)

Psoriasis
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)

Spondylitis, Ankylosing
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)

Crohn's Disease
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)

Psoriasis
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

Heart Failure, Congestive
NovaCardia, Inc.
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Heart Failure, Congestive

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, Germany, Australia, United States, Poland, Spain, Chile, France, Sweden
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Melanoma

Spain, Italy, Poland, Brazil, Australia, Chile, Canada, Portugal, Turkey, Germany, Greece, Israel, Sweden, New Zealand, United States, Belgium, France, Taiwan, United Kingdom, Switzerland, South Africa, Denmark, Argentina
Adagene Inc
Merck Sharp & Dohme LLC

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Korea, Republic of, United States
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Colorectal Neoplasms

United States, Canada, Italy, Argentina, United Kingdom, China, Japan, Belgium, France, Korea, Republic of, Spain, Taiwan, Brazil, Ireland, Netherlands, Australia, Slovakia, Chile, Poland, Norway, Switzerland, Austria, Germany, Portugal, Gree... and more
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

HER2 Positive Breast Cancer

United States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more

Clinical Trials Sponsored by Merck Inc., Philippines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations